Merck & Co. stock: Efinopegdutide clears MASH trial endpoint
Published on 11/21/2026 at 11:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSWhat the trial changes for Merck
- Merck reported positive mid-stage results for efinopegdutide in patients with MASH and liver fibrosis.
- The candidate remains investigational, keeping regulatory progress and safety results central for investors.
On November 9, Merck & Co. announced positive results from a mid-stage trial of efinopegdutide in adults with metabolic dysfunction-associated steatohepatitis and stage F2 or F3 liver fibrosis. The company said the study met its primary endpoint of MASH resolution without worsening of fibrosis after 52 weeks. The announcement was published by Merck.
Pipeline signal for investors
MASH resolution occurred in 56%, 63% and 61% of participants receiving the 4 mg, 7 mg and 10 mg weekly doses, respectively, compared with 13% for placebo. The company also reported improvement of at least one fibrosis stage without worsening of steatohepatitis in 43%, 52% and 34% of the three dose groups, versus 21% for placebo.
Efinopegdutide is an investigational once-weekly treatment that targets GLP-1 and glucagon receptors. Merck said its safety profile was generally consistent with semaglutide, while nausea and treatment discontinuations due to adverse events varied across the dose groups. The candidate has received Fast Track designation from the U.S. Food and Drug Administration.
Merck & Co. stock traded at 121.92 euros on Lang & Schwarz at 11:25 CET on Saturday, November 21, 2026.
Merck & Co. at a glance
- Company: Merck & Co., Inc.
- ISIN: US58933Y1055
- Ticker: MRK
- Home exchange: NYSE
- Lang & Schwarz price: 121.92 euros on November 21, 2026, at 11:25 CET
For broader U.S. market developments, see Current market reports.
